We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical
News

Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical

Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical
News

Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced that it has received a milestone payment from Ono Pharmaceutical Co., Ltd. (Ono) from its research collaboration aimed at identifying novel inhibitors for a protease target. The milestone is received for the progression of the medicinal chemistry collaboration into lead optimization.

The programme success validates again the strength of Evotec’s Fragment Based Drug Discovery platform, EVOlution™, along with its integrated drug discovery capabilities, including biology, medicinal chemistry, structure based drug design and in vitro pharmacology.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We are delighted to have achieved this important milestone with Ono and once again to demonstrate the value that we bring to our partnership with them. The success of this project is a testament to the strong partnership between our two companies and we look forward to continuing working closely with our colleagues at Ono both on this programme as it progresses to the clinic as quickly as possible and also on our recently initiated collaboration on a second target as proactively as possible.”

“We have a high regard for Evotec's drug discovery expertise and the capabilities and technologies used in progressing this collaboration. The achievement of this milestone further validates our strategy to work with the best collaborators in the industry.  We look forward to reaching additional milestones together as our programmes progress”, said Kazuhito Kawabata, Ph.D., Managing Director, Head of Research Headquarters and Director of Minase Research Institute at Ono.

Evotec and Ono are also collaborating on a second target, an ion channel, for which Ono will access Evotec’s ion channel drug discovery platform and expertise. For this second programme Evotec will receive further research funding and milestone payments.
Advertisement